Evidence-based · AI-powered · Non-profit

Oncology Drugs A to Z: FDA Status, Uses & Safety

Browse oncology drugs A to Z with FDA status, approved-use context, safety information, cancer treatment resources, and primary-source links.

Browse oncology drug and regimen pages

Each linked entry has its own crawlable, self-canonical reference page. FDA status and indications can change, so current primary sources are linked whenever a page has been editorially reviewed.

Featured FDA-reviewed oncology drug pages

Pepaxto (Melphalan flufenamide) — U.S. approval withdrawn
Revuforj (Revumenib) — FDA approved for specified biomarker-defined acute leukemias
Avmapki Fakzynja Co-Pack (Avutometinib and defactinib) — FDA accelerated approval for a specified KRAS-mutated ovarian cancer setting
Lifyorli (Relacorilant) — FDA approved in March 2026 for a specified platinum-resistant cancer setting
Zepzelca (Lurbinectedin) — FDA approved for specified small-cell lung cancer settings
Datroway (Datopotamab deruxtecan-dlnk) — FDA approved for specified breast and lung cancer settings

A

B

C

D

E

F

G

H

I

J

Jevtana

K

L

M

N

O

P

Q

Quizartinib (Vanflyta)

R

S

T

V

W

Welireg

X

Y

Z

OncosAI provides educational information only. It does not provide medical advice, diagnosis, or treatment recommendations.